Effects of complication hazards experience on type 2 diabetes patients with poor glycemic control
- VernacularTitle:并发症危害体验对血糖控制不良2型糖尿病患者的影响
- Author:
Lijuan WANG
1
;
Junxiang GAO
;
Shuo KANG
;
Jingjing QIU
;
Yue ZHANG
;
Xiujun ZHAO
Author Information
1. 河北医科大学第二医院内分泌科
- Keywords:
Diabetes,type 2;
Lipid abnormality;
Complications;
Self-management behavior;
Glycosylated hemoglobin
- From:
Chinese Journal of Modern Nursing
2016;22(3):327-331
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the effects of complications hazard experience on self-management behaviors, glycosylated hemoglobin and lipid among type 2 diabetes patients with poor glycemic control. Methods A total of 100 patients with type 2 diabetes were randomly divided into control group (50 cases) and intervention group (50 cases) by random number table. The patients of control group received routine diabetic education, while the patients of intervention group received the hazard experience of complications. All patients of two groups received telephone follow-up for 3 months. Their self-management behaviors, glycosylated hemoglobin and lipid were measured before and 3 months after the intervention. Results There was no statistically significant difference of the score in self-management behaviors, glycosylated hemoglobin and lipid between two groups before the intervention (P>0. 05). After 3 months intervention, the scores of balanced diet, regular exercise, blood glucose monitoring, foot care and the level of blood sugar handling in the intervention group were statistically higher than those in the control group (P <0. 05). The score of fully compliance medication had no statistically significant difference between two groups after the intervention (P>0. 05). The glycosylated hemoglobin, total cholesterol (TC), triglyceride (TG), low density lipoprotein in the intervention group were statistically lower than those in the control group (P<0. 05). Conclusions Hazard experience of complications can improve self-management behaviors, glycosylated hemoglobin and lipid for type 2 diabetes patients with poor glycemic control.
